Skip to content
Screener

Capricor Therapeutics CAPR Q1 2026 earnings

Reported May 12, 2026 · After market close

EPS-$0.59Miss by $0.04
Revenue estimate$40.0M
EPS estimate-$0.55

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$41.7M
EPS estimate-$0.14

Financials

Q1 2026

Income statement

See full
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.75B+303%
Enterprise value$1.66B+308%

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

FAQ

When did Capricor Therapeutics report Q1 2026 earnings?
Capricor Therapeutics (CAPR) reported Q1 2026 earnings on May 12, 2026 after market close.
What were Capricor Therapeutics's Q1 2026 revenue and EPS?
Capricor Therapeutics reported eps of $-0.59 for Q1 2026.
Did Capricor Therapeutics beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.55 by $0.04.
How did Capricor Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 11.3% from $-0.53.
Where can I find Capricor Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-059380) and the 10-Q periodic report (0001104659-26-060382) directly on SEC EDGAR. The filing index links above go to sec.gov.